As we approach the halfway point for 2012, now's a good time to look back at what's happening with the stocks that interest you. By making sure you know the important things that a company accomplished -- as well as the setbacks it experienced -- you can make a better decision about whether it's a smart investment for your portfolio.
Today, let's take a look at Star Scientific
Stats on Star Scientific
|2012 YTD Return||122.9%|
|Market Cap||$708 million|
|Total Revenue, Most Recent Quarter||$1,167,000|
|Year-Over-Year Revenue Growth, Most Recent Quarter||663%|
|Net Loss, Most Recent Quarter||($5,171,000)|
|CAPS Rating (out of 5)||*|
Source: S&P Capital IQ.
Why is Star Scientific's stock up so much?
Historically, many analysts pinned their hopes for Star Scientific on its ability to provide an alternative to traditional cigarettes. Given the huge profits that Altria
But although Star Scientific still sells some tobacco products, it no longer resembles a true tobacco company. Sales of subsidiary Rock Creek Pharmaceuticals' dietary supplements have shot through the roof in recent quarters and are solely responsible for the revenue growth that Star Scientific has seen. With CigRx designed to decrease the desire to smoke and Anatabloc billed as a supplement for anti-inflammatory support, customers have latched on to the new direction Star Scientific is moving in.
Star Scientific has made some big strides so far in 2012. It named golfer Fred Couples as what it calls its Brand Ambassador for Anatabloc, and more important, the company developed a retail relationship with GNC Holdings
But Star Scientific still has plenty of work to do. Bears point to massive share issuance and ongoing losses for the company. In order to justify its massive valuation at roughly 250 times trailing annual revenue, the company will have to deliver on the full promise of its dietary supplements with huge growth continuing well into the future. Anything short of that will likely leave investors disappointed.
Star Scientific is a speculative play with plenty of risk as well as potential reward. If you'd prefer some other stock ideas with longer track records of success, let me invite you to learn about three smart long-term stock plays in the Fool's latest special report. It's yours for the taking and is absolutely free, but don't miss out -- click here and read it today.
Click here to add Star Scientific to My Watchlist, which can find all of our Foolish analysis on it and all your other stocks.
Fool contributor Dan Caplinger doesn't own shares of the companies mentioned. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Fool has a disclosure policy.